Paget's disease of bone: An update

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 6, 2011, Pages 352-358

  Naot, Dorit ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

bisphosphonates; genetics; molecular mechanism; Paget's disease of bone; SQSTM1 mutations

Indexed keywords

ALKALINE PHOSPHATASE; COLONY STIMULATING FACTOR 1; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPORIN; OPTINEURIN; OSTEOPROTEGERIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN RIN3; PROTEIN TM7SF4; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; ZOLEDRONIC ACID;

BONE REMODELING; BONE STRUCTURE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PAGET BONE DISEASE; REMISSION; REVIEW; SQSTM1 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE AND BONES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; MUTATION; OSTEITIS DEFORMANS; POLYMORPHISM, GENETIC;

EID: 80255141802     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32834c3c0b     Document Type: Review

References (56)

1. Mays S. Archaeological skeletons support a northwest European origin for Pagets disease of bone. J Bone Miner Res 2010; 25:1839-1841.
2. Bastin S, Bird H, Gamble G, Cundy T. Pagets disease of bone: becoming a rarity? Rheumatology (Oxford) 2009; 48:1232-1235.
3. Matthews B, Cundy T. Pagets disease of bone. Expert Rev Endocrinol Metab 2009; 4:651-668.
4. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Pagets disease. Hum Mol Genet 2002; 11:2735-2739. (Pubitemid 35214900)
5. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70:1582-1588. (Pubitemid 34533906)
6. Roodman GD. Insights into the pathogenesis of Pagets disease. Ann N Y Acad Sci 2010; 1192:176-180.
7. Falchetti A, Masi L, Brandi ML. Pagets disease of bone: theres more than the affected skeletal -a clinical review and suggestions for the clinical practice. Curr Opin Rheumatol 2010; 22:410-423.
8. McNeill G, Halpenny D, Snow A, et al. Pagets disease of the bone: a review. Rheumatol Int 2009; 29:1253-1254.
9. Michou L, Brown JP. Genetics of bone diseases: Pagets disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. Joint Bone Spine 2010; 78:252-258.
10. Reid IR, Hosking DJ. Bisphosphonates in Pagets disease. Bone 2010; 49:89-94.
11. Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Pagets disease -data to 6.5 years. J Bone Miner Res 2011; 26:2261-2270.
12. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Pagets disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22:142-148. (Pubitemid 46032607)
13. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Pagets disease. N Engl J Med 2005; 353:898-908. (Pubitemid 41247929)
14. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Pagets disease of bone. J Bone Miner Res 2010; 25:20-31.
15. Ralston SH, Campbell MK, Fraser W, et al. The PRISM trial: reply to the editor. J Bone Miner Res 2010; 25:1465-1466.
16. Brown JP. Metabolic bone diseases: treating Paget disease -when matters more than how. Nat Rev Rheumatol 2009; 5:663-665.
17. Reid IR, Cundy T, Bolland MJ, Grey A. Response to publication of PRISM trial. J Bone Miner Res 2010; 25:1463-1464; author reply 1465-1466.
18. Michou L, Morissette J, Gagnon ER, et al. Novel SQSTM1 mutations in patients with Pagets disease of bone in an unrelated multiethnic American population. Bone 2011; 48:456-460.
19. Rea SL, Walsh JP, Ward L, et al. Sequestosome 1 mutations in Pagets disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J Bone Miner Res 2009; 24:1216-1223.
20. Rendina D, Gianfrancesco F, De Filippo G, et al. Epidemiological, clinical, and genetic characteristics of Pagets disease of bone in a rural area of Calabria, Southern Italy. J Endocrinol Invest 2010; 33:519-525.
21. Cundy T, Naot D, Bava U, et al. Familial Pagets disease and SQSTM1 mutations in New Zealand. Calcif Tissue Int 2011; 89:258-264.
22. Gennari L, Gianfrancesco F, Di Stefano M, et al. SQSTM1 gene analysis and gene-environment interaction in Pagets disease of bone. J Bone Miner Res 2010; 25:1375-1384.
23. Visconti MR, Langston AL, Alonso N, et al. Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res 2010; 25:2368-2373.
24. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Pagets disease in offspring inheritingSQSTM1mutations. J Bone Miner Res 2007; 22:411-415. (Pubitemid 46797124)
25. Matthews BG, Naot D, Bava U, et al. Absence of somatic SQSTM1 mutations in Pagets disease of bone. J Clin Endocrinol Metab 2009; 94:691-694.
26. Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Pagets disease of bone. J Bone Miner Res 2009; 24:484-494.
27. Falchetti A, Marini F, Masi L, et al. Genetic aspects of the Pagets disease of bone: concerns on the introduction of DNA-based tests in the clinical practice. Advantages and disadvantages of its application. Eur J Clin Invest 2010; 40:655-667.
28. Seton M, Moses AM, Bode RK, Schwartz C. Pagets disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011; 48:281-285.
29. Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Pagets disease. Cell Metab 2011; 13:23-34.
30. Beyens G, Daroszewska A, de Freitas F, et al. Identification of sexspecific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Pagets disease of bone. J Bone Miner Res 2007; 22:1062-1071. (Pubitemid 351339729)
31. Daroszewska A, Hocking LJ, McGuigan FE, et al. Susceptibility to Pagets disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res 2004; 19:1506-1511. (Pubitemid 41094352)
32. Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Pagets disease of bone. Nat Genet 2010; 42:520-524.
33. Chung PY, Beyens G, Riches PL, et al. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Pagets disease of bone. J Bone Miner Res 2010; 25:2592-2605.
34. Chung PY, Beyens G, Boonen S, et al. The majority of the genetic risk for Pagets disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet 2010; 128:615-626.
35. Albagha OM, Wani SE, Visconti MR, et al. Genome-wide association identifies three new susceptibility loci for Pagets disease of bone. Nat Genet 2011; 43:685-689.
36. Chung PY, Beyens G, de Freitas F, et al. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Pagets disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. Mol Genet Metab 2011; 103:287-292.
37. Corral-Gudino L, del Pino-Montes J, Garcia-Aparicio J, et al. Pagets disease of bone is not associated with common polymorphisms in interleukin-6, interleukin-8 and tumor necrosis factor alpha genes. Cytokine 2010; 52:146-150.
38. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Pagets disease of bone. J Bone Miner Res 2007; 22:298-309. (Pubitemid 46167800)
39. Marshall MJ, Evans SF, Sharp CA, et al. Increased circulating Dickkopf-1 in Pagets disease of bone. Clin Biochem 2009; 42:965-969.
40. Michou L, Chamoux E, Couture J, et al. Gene expression profile in osteoclasts from patients with Pagets disease of bone. Bone 2010; 46:598-603.
41. Ju JS, Weihl CC. Inclusion body myopathy, Pagets disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet 2010; 19:R38-R45.
42. Daroszewska A, Vant Hof RJ, Rojas JA, et al. A point mutation in the ubiquitin associated domain of SQSMT1 is sufficient to cause a Pagets disease like disorder in mice. Hum Mol Genet 2011; 20:2734-2744.
43. Badadani M, Nalbandian A, Watts GD, et al. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One 2010; 5:e13183.
44. Custer SK, Neumann M, Lu H, et al. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19:1741-1755.
45. Chamoux E, Couture J, Bisson M, et al. The p62 P392L mutation linked to Pagets disease induces activation of human osteoclasts. Mol Endocrinol 2009; 23:1668-1680.
46. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome gene associated with increased NF-kappaB signaling and Pagets disease of bone with a severe phenotype. J Bone Miner Res 2006; 21:1136-1145. (Pubitemid 43962843)
47. Yip KH, Feng H, Pavlos NJ, et al. p62 Ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Pagets disease of bone. Am J Pathol 2006; 169:503-514. (Pubitemid 44156310)
48. Layfield R. The molecular pathogenesis of Pagets disease of bone. Expert Rev Mol Med 2007; 9:1-12.
49. Garner TP, Long JE, Layfield R, Searle MS. Impact of p62/SQSTM1 UBA domains mutations linked to Pagets disease of bone on ubiquitin recognition. Biochemistry 2011; 50:4665-4674.
50. Long J, Garner TP, Pandya MJ, et al. Dimerisation of the UBA domain of p62 inhibits ubiquitin binding and regulates NF-kappaB signalling. J Mol Biol 2010; 396:178-194.
51. Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Pagets disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005; 20:619-624. (Pubitemid 40393070)
52. Cavey JR, Ralston SH, Sheppard PW, et al. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Pagets disease of bone. Calcif Tissue Int 2006; 78:271-277. (Pubitemid 43725186)
53. Najat D, Garner T, Hagen T, et al. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Pagets disease of bone. J Bone Miner Res 2009; 24:632-642.
54. Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010; 143:682-685.
55. Heinen C, Garner TP, Long J, et al. Mutant p62/SQSTM1 UBA domains linked to Pagets disease of bone differ in their abilities to function as stabilization signals. FEBS Lett 2010; 584:1585-1590.
56. Hocking LJ, Mellis DJ, McCabe PS, et al. Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts. Biochem Biophys Res Commun 2010; 402:543-548.